AL001是由Alector(NASDAQ:ALEC)开发的一种抗SORT1/Sortilin单抗,提高PGRN的水平,实现对神经退行性疾病的治疗。人类和小鼠的遗传研究已经确认SORT1是血浆和大脑中PGRN水平的主要负调节因子。SORT1是细胞表面以及细胞内内质网高尔基体上的分选受体。SORT1在血浆和大脑中与细胞外PGRN结合,并将其转运到细胞内由溶酶体降解,...
Alector公司和葛兰素史克(GSK)公司近日宣布建立合作伙伴关系,共同开发两种促进progranulin(颗粒蛋白前体,PGRN)蛋白质生产的实验性抗体——AL001和AL101——作为肌萎缩侧索硬化症(ALS)等神经退行性疾病的潜在治疗药物。 根据合作协议,Alector将获得高达22亿美元的付款,并在2期概念验证研究期间继续负责AL001和AL101的临床...
Michael WardAlector, Inc. South San Francisco CA USAMackenzie HageyAlector, Inc. South San Francisco CA USAOmer SiddiquiAlector, Inc. South San Francisco CA USARobert PaulAlector, Inc. South San Francisco CA USAJohn Wiley & Sons, LtdAlzheimer's & Dementia...
In the brain, progranulin (PGRN) is a key regulator of microglia activity and lysosomal function. AL001 is a human monoclonal IgG1 antibody that blocks and downregulates Sortilin, a receptor in the key degradation pathway of PGRN, and is being developed by Alector for the treatment of ...
Therefore, blocking Sortilin/PGRN interactions provides a therapeutic strategy for sustaining levels of functional secreted PGRN in the central nervous system (CNS) with the potential to minimize progression of FTD-associated dementias.Design/Methods: Alector has generated a therapeutic candidate human ...